Meanwhile, knocking down SYTL4 in organoids improved the tumor sensitivity to paclitaxel (Figure 4I-J), suggesting that SYTL4 may serve as a potential therapeutic target for paclitaxel resistance in TNBC. Here, SYTL4 is linked to neoplasm.